Junko Tanizaki

5PUBLICATIONS
22CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

Hisao Imai, Takashi Kijima, Koichi Azuma

|Dec 18, 2021
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi

|Dec 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda

|Aug 08, 2021
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura

Pageof 1

Frequent Collaborators

3 joint publications

Koji Haratani

3 joint publications

Hidetoshi Hayashi

3 joint publications

Kazuhiko Nakagawa

2 joint publications

Kimio Yonesaka